Tempest Therapeutics (TPST) Revenue & Revenue Breakdown
Tempest Therapeutics Revenue Highlights
0
Latest Revenue (Q)
$486.00K
Tempest Therapeutics Revenue by Period
Tempest Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $295.00K | -54.82% |
| 2016-12-31 | $653.00K | 135.74% |
| 2015-12-31 | $277.00K | -97.15% |
| 2014-12-31 | $9.73M | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | - |
Tempest Therapeutics generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Tempest Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $486.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $3.56M | 6363.64% |
| 2018-09-30 | $55.00K | -32.10% |
| 2018-06-30 | $81.00K | 20.90% |
| 2018-03-31 | $67.00K | -26.37% |
| 2017-12-31 | $91.00K | 62.50% |
| 2017-09-30 | $56.00K | -33.33% |
| 2017-06-30 | $84.00K | 33.33% |
| 2017-03-31 | $63.00K | -47.93% |
| 2016-12-31 | $121.00K | -38.58% |
| 2016-09-30 | $197.00K | 4.23% |
| 2016-06-30 | $189.00K | 29.45% |
| 2016-03-31 | $146.00K | -7.01% |
| 2015-12-31 | $157.00K | 109.33% |
| 2015-09-30 | $75.00K | 150.00% |
| 2015-06-30 | $30.00K | 100.00% |
| 2015-03-31 | $15.00K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Tempest Therapeutics generated $486.00K in revenue during Q4 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Tempest Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| GLUE | Monte Rosa Therapeutics | $75.62M | $60.65M |
| ZNTL | Zentalis Pharmaceuticals | $67.42M | $26.86M |
| RNXT | RenovoRx | $43.00K | $197.00K |
| IKNA | Ikena Oncology | - | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| CGEM | Cullinan Oncology | - | - |
| FBRX | Forte Biosciences | - | - |
| INDP | Indaptus Therapeutics | - | - |
| RVMD | Revolution Medicines | - | - |
| SANA | Sana Bio | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| AKTX | Akari Therapeutics | - | - |
| PCSA | Processa Pharmaceuticals | - | - |
| TPST | Tempest Therapeutics | - | $486.00K |
| LYEL | Lyell Immunopharma | - | $11.00K |